S&P 500 jumps as AMD rally leads tech higher
BioNTech SE (NASDAQ:BNTX) announced Monday that it has amended and restated its global co-development and co-commercialization agreement with Bristol-Myers Squibb Company for the investigational bispecific antibody BNT327, targeting multiple solid tumor types. The updated agreement, originally signed on June 2, 2025, was amended on August 15, 2025, according to a statement based on a recent SEC filing.
Under the terms of the revised agreement, Bristol-Myers Squibb (BMS) will pay BioNTech $1.5 billion as an upfront payment. In addition, BioNTech is set to receive $2 billion in non-contingent anniversary payments through 2028. The company is also eligible for up to $7.6 billion in further development, regulatory, and commercial milestone payments. The two firms will share global profits and losses equally.
The collaboration involves joint development, manufacturing, and commercialization of BNT327. Both companies have agreed to use commercially reasonable efforts to jointly develop BNT327 as a monotherapy or in combination with other products, with costs generally shared equally. If either party proposes new clinical trials for additional indications or combinations, the other party can choose whether to co-fund; if not, the proposing party may proceed independently at its own expense.
Commercialization responsibilities will also be shared, coordinated by a joint committee. BioNTech will initially handle global clinical supply of BNT327 until manufacturing technology is transferred to BMS. After the transfer, BMS will be responsible for commercial supply, with BioNTech retaining the right to contribute a portion.
The agreement includes mutual co-exclusive intellectual property licenses and a mutual right of first negotiation related to next-generation antibodies for five years. The term of the agreement is indefinite unless terminated by mutual agreement or under specified conditions, including material breach, insolvency, or safety concerns. Upon certain terminations, BioNTech may receive a reversion license to continue developing and commercializing BNT327, subject to agreed financial terms.
This information is based on a statement from BioNTech SE’s recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.